论文部分内容阅读
检测肝细胞癌患者肿瘤组织中TBC1D4的蛋白表达及其诱导的自身体液免疫应答,为肝细胞癌患者进行特异性免疫治疗提供部分依据。原核表达,镍鳌合亲和白纯化TBC1D4蛋白分子,免疫组化检测26例肝细胞癌患者癌组织的TBC1D4表达;ELISA方法测定96肝细胞癌患者与150例健康对照者血清中抗TBC1D4蛋白抗体的水平。表达纯化了重组蛋白TBC1D4,并诱导出多克隆抗体。26例癌组织中,9例(34.6%,9/26)TBC1D4蛋白表达水平增高;96例患者血清中,17例(17.7%,17/96)血清抗TBC1D4蛋白抗体阳性,150例健康对照者血清全部为阴性。患者组抗体阳性率显著高于健康对照组(P<0.01)。结论认为,TBC1D4蛋白分子在肝细胞癌组织中表达增高,并具有免疫原性,可能是肝细胞癌免疫治疗的一个良好的靶抗原。
To detect the expression of TBC1D4 protein and its own humoral immune response in the tumor tissue of patients with hepatocellular carcinoma and to provide some evidence for the specific immunotherapy of patients with hepatocellular carcinoma. TBC1D4 protein was purified by nickel chelate affinity purification and TBC1D4 protein expression was detected by immunohistochemistry in 26 cases of HCC. The levels of TBC1D4 protein in serum of 96 hepatocellular carcinoma patients and 150 healthy controls were measured by ELISA s level. The recombinant protein TBC1D4 was expressed and purified, and a polyclonal antibody was induced. TBC1D4 protein expression was increased in 9 cases (34.6%, 9/26) of 26 cancer tissues. Serum samples from 17 patients (17.7%, 17/96) were positive for anti-TBC1D4 antibody in serum of 96 patients and 150 healthy controls Serum all negative. The antibody positive rate of patient group was significantly higher than that of healthy control group (P <0.01). Conclusions: TBC1D4 protein is highly expressed in hepatocellular carcinoma and is immunogenic, which may be a good target antigen for hepatocellular carcinoma immunotherapy.